Low Expression of Stanniocalcin 1 (STC-1) Protein Is Associated With Poor Clinicopathologic Features of Endometrial Cancer

Näytä kaikki kuvailutiedot




Khatun , M , Urpilainen , E , Ahtikoski , A , Arffman , R K , Pasanen , A , Puistola , U , Tapanainen , J S , Andersson , L C , Butzow , R , Loukovaara , M & Piltonen , T T 2021 , ' Low Expression of Stanniocalcin 1 (STC-1) Protein Is Associated With Poor Clinicopathologic Features of Endometrial Cancer ' , Pathology and Oncology Research , vol. 27 , 1609936 . https://doi.org/10.3389/pore.2021.1609936

Julkaisun nimi: Low Expression of Stanniocalcin 1 (STC-1) Protein Is Associated With Poor Clinicopathologic Features of Endometrial Cancer
Tekijä: Khatun, Masuma; Urpilainen, Elina; Ahtikoski, Anne; Arffman, Riikka K.; Pasanen, Annukka; Puistola, Ulla; Tapanainen, Juha S.; Andersson, Leif C.; Butzow, Ralf; Loukovaara, Mikko; Piltonen, Terhi T.
Tekijän organisaatio: Department of Pathology
University of Helsinki
HUS Gynecology and Obstetrics
Reproductive Disease Modeling
Department of Obstetrics and Gynecology
Helsinki University Hospital Area
Päiväys: 2021-09-28
Kieli: eng
Sivumäärä: 9
Kuuluu julkaisusarjaan: Pathology and Oncology Research
ISSN: 1219-4956
DOI-tunniste: https://doi.org/10.3389/pore.2021.1609936
URI: http://hdl.handle.net/10138/335887
Tiivistelmä: Stanniocalcin-1 (STC-1) is a glycoprotein hormone involved in diverse biological processes, including regulation of calcium phosphate homeostasis, cell proliferation, apoptosis, inflammation, oxidative stress responses, and cancer development. The role of STC-1 in endometrial cancer (EC) is yet to be elucidated. In this study, we investigated the protein expression pattern of STC-1 in a tissue microarray (TMA) cohort of hysterectomy specimens from 832 patients with EC. We then evaluated the prognostic value of STC-1 expression regarding the clinicopathologic features and patients survival over a period of 140 months. Our results revealed that in EC tissue samples, STC-1 is mainly localized in the endometrial epithelium, although some expression was also observed in the stroma. Decreased STC-1 expression was associated with factors relating to a worse prognosis, such as grade 3 endometrioid tumors (p = 0.030), deep myometrial invasion (p = 0.003), lymphovascular space invasion (p = 0.050), and large tumor size (p = 0.001). Moreover, STC-1 expression was decreased in tumors obtained from obese women (p = 0.014) and in women with diabetes mellitus type 2 (DMT2; p = 0.001). Interestingly, the data also showed an association between DNA mismatch repair (MMR) deficiency and weak STC-1 expression, specifically in the endometrial epithelium (p = 0.048). No association was observed between STC-1 expression and disease-specific survival. As STC-1 expression was particularly low in cases with obesity and DMT2 in the TMA cohort, we also evaluated the correlation between metformin use and STC-1 expression in an additional EC cohort that only included women with DMT2 (n = 111). The analysis showed no difference in STC-1 expression in either the epithelium or the stroma in women undergoing metformin therapy compared to metformin non-users. Overall, our data may suggest a favorable role for STC-1 in EC behavior; however, further studies are required to elucidate the detailed mechanism and possible applications to cancer treatment.
Kuvaus: Publisher Copyright: © Copyright © 2021 Khatun, Urpilainen, Ahtikoski, Arffman, Pasanen, Puistola, Tapanainen, Andersson, Butzow, Loukovaara and Piltonen.
Avainsanat: 3111 Biomedicine
disease-specific survival
endometrioid carcinoma
type 2 diabetes mellitus
uterine cancer
3123 Gynaecology and paediatrics
Vertaisarvioitu: Kyllä
Tekijänoikeustiedot: cc_by
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: publishedVersion


Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
pore_27_1609936.pdf 1.493MB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot